Life Science Success
On this podcast, you'll find interviews with high-performing successful individuals in Life Sciences. On a weekly basis, we cover their proven methods, principles, strategies, and mindsets to implement new technologies that scale to meet the needs of people in our world.
info_outline
Revolutionizing Medicine: DoseMeRx's Journey to Smarter Dosing!
05/12/2024
Revolutionizing Medicine: DoseMeRx's Journey to Smarter Dosing!
Paul Edwards is the President and CEO of DoseMeRx. He has been a Senior Executive with Merck and GSK, and start-ups including ILUM Health Solutions, Infectious Disease Connect, and TrackMy Solutions. He has an extensive history in infectious disease, antimicrobial stewardship, and precision medicine. Guest Introduction: Paul Edwards, the President and CEO of DoseMeRx, shares his extensive background in the pharmaceutical industry, including roles at Merck, GSK, and various startups, focusing on antibiotics and infectious diseases. Pharmaceutical Journey: Paul discusses his career progression from selling macrolides to leading infectious disease units and moving to the U.S. to transform commercial models at Merck, emphasizing the importance of real-world data over clinical trial data. DoseMeRx Focus: DoseMeRx specializes in precise dosing for critically ill patients using therapeutic drug monitoring, particularly for injectable antibiotics, aiming to provide accurate dosing information through web-based and integrated models within hospital systems. Challenges and Future of Medicine: Paul highlights the importance of antimicrobial stewardship, pharmacogenomics, and personalized medicine in improving patient care and expresses concerns about the current insurance and payment systems based on actuarial science.
/episode/index/show/lssuccess/id/31253502
info_outline
Meet Dr. Amado: Leading Cancer Research at Zai Lab
04/26/2024
Meet Dr. Amado: Leading Cancer Research at Zai Lab
In this episode of the Life Science Success Podcast, I am joined by Dr. Rafael G. Amado, an esteemed leader in oncology research and development, currently serving as the President and Head of Global Oncology at Zai Lab. With a distinguished career spanning multiple leading biotech firms, Dr. Amado brings a wealth of experience in gene-engineered cell therapies and innovative cancer treatments. Professional Background: Dr. Rafael G. Amado is currently the president and head of global oncology at Zai Lab. He has a rich background in medicine, starting with his education in Spain, followed by a move to the U.S. where he specialized in Internal Medicine and later Hematology Oncology at the University of California, Los Angeles. Passion for Oncology: Dr. Amado's interest in oncology stems from its complex nature and the multifaceted approach it requires, combining diagnostics, therapeutics, and a detective-like inquiry into patient cases. His career shift towards oncology was influenced by its holistic approach to patient care and his personal drive to solve complex medical puzzles. Research and Development Focus: At Zai Lab, Dr. Amado oversees oncology research and development, focusing on gene-engineered cell therapies among other innovative treatments. He has been involved in significant breakthroughs, such as determining drug inefficacies in patients with certain genetic mutations, which has influenced global regulatory changes in cancer treatment. Corporate and Global Strategy: Under Dr. Amado’s leadership, Zai Lab has approved six drugs in China, with a strong emphasis on addressing grievous illnesses through open innovation. He is instrumental in expanding the company's global reach, aiming to impact a broad patient base internationally by aligning clinical trials and regulatory strategies across diverse geographic locations. Vision and Future Goals: Dr. Amado is committed to advancing drug development that significantly outweighs potential risks with therapeutic benefits. He is driven by a mission to impact oncology treatment on a global scale, with ambitious goals to reach approximately a million patients by 2030 through continuous innovation and strategic drug development.
/episode/index/show/lssuccess/id/31008083
info_outline
Revolutionizing GI Cancer Detection with Previse | Dan Lunz CEO
04/21/2024
Revolutionizing GI Cancer Detection with Previse | Dan Lunz CEO
This week on the Life Science Success Podcast my guest is Dan Lunz. Dan Lunz is the CEO and Co-founder of Previse, a pioneering company based in Baltimore, Maryland, that specializes in offering tests for the prediction and earlier detection of upper-GI cancers. Background of Dan Lunz: Dan Lunz, CEO and co-founder of Previse, shares his journey from growing up in Baltimore, serving in the Marine Corps, experiencing healthcare firsthand as a patient in the VA system, to studying at Johns Hopkins and working in clinical research. His career path was significantly influenced by his desire to serve others, leading him to the life sciences sector. Formation of Previse: Lunz's collaboration with Dr. Steven Meltzer, a professor at Johns Hopkins, sparked the founding of Previse. They focused on developing diagnostic tools for early detection of upper GI cancers based on Meltzer's research on biomarkers. Their shared mission was to improve patient outcomes through innovative medical technologies. Previse's Diagnostic Innovations: Previse specializes in detecting and predicting upper gastrointestinal (GI) cancers. The company offers a commercial test called ESO Predict, which assesses the risk of esophageal cancer in patients with conditions like Barrett's esophagus, helping physicians strategize patient management and surveillance intervals. Challenges and Leadership Insights: Throughout the interview, Lunz discusses the entrepreneurial challenges of securing funding and navigating regulatory landscapes. He emphasizes the importance of perseverance and humility in leadership, learning from rejections, and the critical role of assembling a talented team to overcome complex challenges. Future Goals and Impact: Looking forward, Previse aims to expand access to its existing diagnostics across the U.S. and continue developing non-endoscopic tools and medical devices to enhance GI cancer detection. Lunz is driven by the potential impact of their technology in preventing cancer and improving patient care, underscoring his dedication to service and innovation in life sciences.
/episode/index/show/lssuccess/id/30921888
info_outline
Innovating Biopharma & Pioneering Critical Care Solutions - Leonard Mazur
04/21/2024
Innovating Biopharma & Pioneering Critical Care Solutions - Leonard Mazur
In this episode of the Life Science Success Podcast our guest is Leonard Mazur, CEO and Co-Founder of Citius Pharmaceuticals. With over 50 years of experience in the biopharma industry, Leonard has been at the forefront of developing groundbreaking therapies for patients with unmet medical needs. Background and Entry into Biopharmaceuticals: Leonard Mazur, CEO and co-founder of Citius Pharmaceuticals, began his career through an unexpected newspaper ad, leading him to pharmaceutical sales. His liberal arts background as a psychology major did not initially suggest a career in biopharma, highlighting the unpredictability of career paths. Early Career Development: Mazur's rapid career advancement occurred within Cooper Laboratories, an entrepreneurial company where he transitioned from sales to marketing and strategic planning. This period involved substantial growth through acquisitions, providing him with a broad range of experiences in the pharmaceutical sector. Entrepreneurial Ventures: Throughout his career, Leonard Mazur has initiated multiple entrepreneurial efforts, ultimately leading to the founding of Citius Pharmaceuticals. His story is marked by significant risk-taking, including personal financial stakes in business initiatives, reflecting his deep commitment to his entrepreneurial pursuits. Focus of Citius Pharmaceuticals: Citius Pharmaceuticals, which Mazur co-founded, is dedicated to developing innovative treatments for critical care. A key product from Citius is an antibiotic lock solution for treating infections in central venous catheters, illustrating the company's commitment to addressing complex medical needs. Views on Industry and Innovation: Mazur discusses the critical role of the biopharmaceutical industry in global drug development, emphasizing the potential risks to innovation from policy changes such as the implementation of socialized medicine. His insights reflect on the industry's dynamics and the importance of sustaining an environment conducive to pharmaceutical innovation.
/episode/index/show/lssuccess/id/30920158
info_outline
CPA to Biotech Innovator & Coach - Marc Cote
04/15/2024
CPA to Biotech Innovator & Coach - Marc Cote
In this episode of Life Science Success, we sit down with Marc, an entrepreneur, certified coach, and a beacon of leadership in the life sciences and business coaching sectors. Marc shares his journey from the entrepreneurial services group at EY to founding and leading companies in the life sciences field, and how he leverages his vast experience to mentor and inspire others towards professional excellence and personal growth. Tune in for a deep dive into the intersection of business acumen and scientific innovation, and discover Marc's unique approach to fostering success in the competitive world of life sciences. Marc Cote's background includes a transition from being a CPA at Ernst & Young to becoming an entrepreneur and certified coach, focusing on leadership within the life sciences. He credits his father, a second-generation business owner, for influencing his career path and emphasizing the importance of a strong business foundation. During his career, Cote identified a gap in leadership and soft skills training among highly technically trained professionals in the life sciences. He aims to help these individuals realize their potential not only as scientists but also as visionary leaders and effective managers. Cote discusses his journey from consulting at Ernst & Young to launching his own companies that supported biotech and small pharmaceutical companies. He emphasizes the value of leadership coaching to enhance emotional intelligence (EQ), crucial for effective leadership. The podcast conversation covers Cote's approach to coaching, focusing on understanding and leveraging one's strengths and appreciating different leadership styles. He highlights the importance of continuous personal development and adaptability in achieving career advancement within the life sciences.
/episode/index/show/lssuccess/id/30833453
info_outline
Building the Future of Life Sciences - Darwin Shurig
04/13/2024
Building the Future of Life Sciences - Darwin Shurig
In this episode of Life Science Success, my guest is Darwin Shurig, founder and CEO of Shurig Solutions. Darwin brings strategic value to medical device, life science, and pharma companies. Darwin is responsible for most, if not all, business processes, including project management, recruitment, sales, operations, quality, and regulatory affairs, to mention a few. Guest Introduction: Darwin Shurig, the guest, is introduced as the founder and president of a company involved in the recruitment industry, particularly within the life sciences sector. Darwin shares his journey of starting the business, highlighting his prior experience in clinical respiratory therapy and his transition to entrepreneurship nearly nine years ago. Business Challenges and Insights: Darwin discusses the challenges he faced as a newcomer to the business and recruitment industries. He emphasizes the importance of resilience, learning from failures, and the critical role of understanding market needs and analytics to sustain a business in a competitive environment. Recruitment Philosophy and Strategies: Throughout the interview, Darwin explains his approach to recruitment, focusing on the importance of specialization, understanding client needs, and delivering value without having to return fees. He stresses a high client acceptance rate and successful placement track record as indicators of his company's effectiveness. Industry Perspective and Future Outlook: Closing the conversation, Darwin reflects on the broader industry trends, including the impact of technology like AI on recruitment and other business processes. He is optimistic about the potential of new technologies to enhance business efficiency and expresses curiosity about future developments in life sciences and AI.
/episode/index/show/lssuccess/id/30810938
info_outline
Dr. Mohit Jain Unveils Next-Gen Tech in Drug Discovery & Therapy
04/06/2024
Dr. Mohit Jain Unveils Next-Gen Tech in Drug Discovery & Therapy
In this episode of Life Science Success, host Don Davis has a conversation with Dr. Mohit Jain, a physician scientist with extensive experience in physiology, biomedicine, and mass spectrometry. Dr. Jain shares his unique journey from clinical training to leading breakthroughs in mass spectrometry and computational biology. He discusses the inception of Sapient Bio, a company that leverages mass spectrometry to unlock new horizons in drug discovery and patient diagnosis by analyzing thousands of molecules in the human body. They explore the future of medicine, emphasizing personalized therapy and the potential to diagnose diseases like diabetes and Alzheimer's years in advance. Dr. Jain also sheds light on the challenges and opportunities in biotech, the impact of computational biology, and the pivotal role of Sapient Bio in pioneering the field of drug discovery. The conversation concludes with Dr. Jain's reflections on leadership, inspiration, concerns, and what excites him about his work, offering deep insights into the promising future of life sciences. Key Highlights: 01:23 Introducing Dr. Mohit Jain: A Multifaceted Scientist 02:04 The Journey to Sapient Bio: Unraveling Dr. Jain's Career Path 03:39 The Evolution of Mass Spectrometry and Its Impact on Health 06:45 Sapient Bio: Democratizing Access to Advanced Technologies 13:33 Challenges and Opportunities in Leading a Biotech Company 16:54 The Future of Drug Discovery and Personalized Medicine 23:47 Sapient Bio's Differentiation and Future Prospects 29:24 Leadership Insights and Personal Reflections from Dr. Jain
/episode/index/show/lssuccess/id/30709448
info_outline
Innovating Life Sciences: Inside Talk with CEO Jennifer Hawks Bland
03/23/2024
Innovating Life Sciences: Inside Talk with CEO Jennifer Hawks Bland
Jennifer Hawks Bland is a distinguished leader in the life sciences sector, serving as the Chief Executive Officer of NewYorkBIO, an organization at the forefront of advancing New York's life sciences ecosystem. With a rich background spanning legal practice, government affairs, and executive leadership in companies like Merck and GlaxoSmithKline, she brings a wealth of experience and insight to her role in fostering innovation and growth within the industry. Jennifer Hawks Bland, CEO of New York Bio, discussed her unique path into life sciences, transitioning from a legal background where she initially engaged with the pharmaceutical industry through mass tort defense litigation, to advocacy and lobbying roles, eventually leading her to her current position. She detailed the mission and operations of New York Bio, highlighting its role in advancing New York’s life sciences ecosystem by collaborating with early-stage companies, academic medical centers, and leveraging the state’s rich resources in life sciences for regional and statewide economic development. Hawks Bland emphasized the importance of storytelling in advocacy, drawing on her legal and lobbying background to influence policy and support the life sciences industry, both at the state and federal levels, and how this skill has been crucial in her roles leading up to and including her leadership at New York Bio. The conversation also covered the challenges and opportunities facing the life sciences sector, particularly in New York, from fostering startup growth to navigating policy and funding landscapes. She stressed the significance of collaboration across various stakeholders, including government, academia, and the private sector, to drive innovation and support the ecosystem. Hawks Bland shared her excitement for the future of life sciences, reflecting on the potential for breakthroughs in health and medicine, and the critical role of advocacy and strategic partnerships in overcoming challenges and capitalizing on opportunities within the industry.
/episode/index/show/lssuccess/id/30510553
info_outline
Advancing ClinicalTrials: Tigermed's Britney Winterberger
03/23/2024
Advancing ClinicalTrials: Tigermed's Britney Winterberger
In this episode of Life Science Success, we're thrilled to welcome Britney Winterberger, the Senior Director of North America Project Management and Clinical Operations at Tigermed. Britney brings a wealth of experience in clinical trials across various therapeutic areas and a deep personal commitment to advancing patient treatments, particularly in the fight against cancer. Britney Winterberger is the Senior Director of North America Project Management and Clinical Operations at Tigermed, with a rich career history in life sciences, inspired by a personal loss to leukemia. She initially aspired to be a pediatric oncologist but shifted towards clinical research to contribute to cancer treatment advancements. Winterberger, who was born and raised in Cincinnati, Ohio, has a Marquette University undergraduate degree in biological sciences as well as study abroad experiences. She is also a family person, emphasizing the importance of travel, outdoor activities, and being sports enthusiasts with her husband and two children. Her journey into the field of life sciences was somewhat unintentional, transitioning from a goal in pediatric oncology to clinical research due to the emotional challenges of the former. She transitioned because of a special opportunity through a family connection, which led her to a career in clinical research organizations (CROs). Throughout her career, pivotal moments included receiving a 'B' on a performance review, which was a significant learning experience for her, highlighting the importance of adaptability, innovation, and the need to work in a more agile and innovative environment. Joining Tigermed represented a culminating point where she found a space to innovate and drive meaningful change in the clinical research landscape. Winterberger discusses the evolution of clinical trials, emphasizing the shift towards patient-centric approaches, the integration of digital health technologies, and the push for decentralized clinical trials to improve patient access and compliance. She also highlights Tigermed's role in advancing clinical research through innovative trial designs and efficient patient recruitment strategies, underlining her commitment to making a difference in cancer treatment and patient care.
/episode/index/show/lssuccess/id/30510483
info_outline
Exploring Biotech Frontiers with Dr. Rahul Kakkar - CEO of Tome Biosciences
03/17/2024
Exploring Biotech Frontiers with Dr. Rahul Kakkar - CEO of Tome Biosciences
In this episode of Life Science Success my guest is Dr Dr. Rahul Kakkar we will dive into the life and innovations of his tremendous career. From founding groundbreaking biotech companies to his vital role at Tome Biosciences and balancing life as a practicing physician, Rahul's journey is nothing short of inspirational. Discover the cutting-edge of genomic medicine and get a peek into the mind of a true life sciences pioneer. Dr. Rahul Kakkar's Journey: Dr. Kakkar, CEO of Tome Biosciences and a distinguished biotech executive and physician scientist, shares his journey from training in the Harvard Hospital System to his disillusionment with academia's limitations on drug development. This frustration led him towards a career in biotech, underscored by his entrepreneurial spirit and the significant influence of mentors who supported him at pivotal moments. Entrepreneurial Shift and Tome Biosciences: His experiences, particularly at AstraZeneca, highlighted the challenges of navigating entrenched corporate cultures, sparking his entrepreneurial journey. This journey includes the founding of Corvidia Therapeutics and ultimately leading to his current role at Tome Biosciences, where he emphasizes a flat, open company culture focused on innovative drug development. Balancing Medicine and Leadership: Kakkar balances his roles as a physician and a biotech leader, finding real-world clinical experiences vital for grounding his work in biotech. He maintains an active part in patient care, which he finds complements his leadership in biotech, keeping his work relevant and impactful. Advancements in Biotech and Tome's Focus: Kakkar discusses the evolution of biotechnology, from monoclonal antibodies and nucleotide-based therapeutics to the future of DNA editing. At Tome Biosciences, the focus is on programmable genomic integration, aiming to create differentiated, impactful drugs. This approach underscores the importance of technology in developing meaningful new therapies. Leadership Philosophy and Inspiration: Sharing insights on leadership, Dr. Kakkar emphasizes the importance of resilience, adaptability, and making the best of situations. He finds inspiration in the human spirit's perseverance, whether in family, healthcare, or scientific discovery, driving him to overcome challenges in healthcare and biotech innovation.
/episode/index/show/lssuccess/id/30409658
info_outline
The Power of GenAI in Life Sciences - Elizabeth Smalley ArisGlobal
03/17/2024
The Power of GenAI in Life Sciences - Elizabeth Smalley ArisGlobal
This week on Life Science Success, we are thrilled to welcome back Elizabeth Smalley as our guest. Elizabeth is the VP, Product Management, Data & Analytics at ArisGlobal, where she plays a pivotal role in steering the company’s strategic initiatives in the realms of artificial intelligence and machine learning within the life sciences sector. With an impressive background that bridges technology and life sciences, Elizabeth has been instrumental in the formation and launch of the GenAI Council, an innovative effort aimed at harnessing generative AI to revolutionize research and development in life sciences. Introduction of Guests and Focus: Don, a consultant in life sciences, introduces Elizabeth Smalley, VP of Product Management, Data, and Analytics at ArisGlobal. The discussion emphasizes the transformative power of generative AI (GenAI) in the life sciences sector, with a particular focus on Elizabeth's leadership in strategic AI initiatives at ArisGlobal. Elizabeth Smalley's Background and Journey: Elizabeth recounts her diverse experience in product management across e-commerce, manufacturing, and healthtech. Her story highlights the central role of AI in her career, including significant achievements in developing AI-driven clinical solutions at Teladoc Health and her progression to leading ArisGlobal's data, analytics, and AI strategies. ArisGlobal's Innovations and Role: The conversation explores ArisGlobal's impact on life sciences, especially its innovative use of AI in pharmacovigilance and regulatory processes. Elizabeth points out ArisGlobal's pioneering introduction of AI into case processing workflows and its leadership in adopting generative AI, aiming to enhance efficiency and patient safety in the sector. Generative AI: Challenges and Opportunities: Elizabeth discusses the economic potential of generative AI in life sciences, acknowledging regulatory challenges and the necessity of industry-wide collaboration to navigate these. She emphasizes the importance of creating a responsible AI adoption playbook, addressing transparency, and fostering innovation within a regulatory framework. Vision for the Future: The interview concludes with a forward-looking view on how generative AI could revolutionize patient care, streamline drug development, and optimize regulatory compliance. Elizabeth advocates for a collaborative approach to leverage AI responsibly, aiming to improve health outcomes, enhance operational efficiencies, and ensure patient safety in the evolving landscape of life sciences.
/episode/index/show/lssuccess/id/30408958
info_outline
Frontiers of the Mind: Dr. Tiago Reis Marques on Transforming Psychiatry and Pioneering CNS Therapeutics
03/09/2024
Frontiers of the Mind: Dr. Tiago Reis Marques on Transforming Psychiatry and Pioneering CNS Therapeutics
This week on the Life Science Success Podcast, my guest is Dr. Tiago Reis Marques Dr. Marques is a psychiatrist and currently the Chief Executive Officer of Pas i thea Therapeutics. Pasithea is developing new molecular entities for the treatment of CNS disorders, including Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis, Neurofibromatosis type 1 and Noonan syndrome. On this episode of Life Science Success, Don Davis interviews Dr. Tiago Reis Marques, the CEO of PACEA Therapeutics. They discuss Dr. Marques's journey in psychiatry, the company's focus on CNS disorders, their pipeline of drugs targeting neurological conditions like schizophrenia and ALS, and the impact of their research on rare disorders like neurofibromatosis type one. The conversation also touches on leadership advice, inspiration, concerns about global issues, and what excites them. Dr. Tiago Reis Marques, a psychiatrist, is the CEO of Pasithea Therapeutics, a company focused on central nervous system (CNS) disorders. His background in medical research and his transition from academia to biotech were driven by a desire to apply his knowledge to develop treatments that benefit patients. Pasithea Therapeutics, co-founded with Professor Steinman from Stanford, aims to create innovative therapies for unmet needs in CNS disorders. The company's approach balances new drugs targeting novel mechanisms of action with known drugs repurposed for new applications. One of the company's focuses is on neurofibromatosis type one, a disorder affecting around 100,000 patients in the US, highlighting the company's commitment to tackling rare and challenging diseases with significant unmet needs. Marques emphasizes the importance of precision psychiatry and targeting specific subtypes of disorders, drawing parallels to how cancer treatments have evolved to focus on specific biomarkers and subtypes, reflecting a broader trend towards personalized medicine. His experiences and work in brain imaging, specifically with positron emission tomography (PET) and psychopharmacology, underscore his multidisciplinary approach to understanding and treating CNS disorders, leveraging his academic background to inform his leadership and strategic direction at Pasithea Therapeutics.
/episode/index/show/lssuccess/id/30302813
info_outline
Revolutionizing Drug Development: Toban Zolman's Journey from Electronic Submissions Pioneer to CEO of Kivo
03/09/2024
Revolutionizing Drug Development: Toban Zolman's Journey from Electronic Submissions Pioneer to CEO of Kivo
In the interview, Don Davis PhD, MBA talks to Toban Zolman about his company, Kivo. Zolman takes us through his impressive journey of over 20 years in life sciences and the transformation he has witnessed in the industry. He further details the services of Kivo, stating that the company helps businesses involved in life sciences, specifically those developing clinical trials for pharmaceutical, medical device, and biotech companies, to streamline and optimize their processes. He specifically speaks about the significant shift in the industry from large pharmaceutical companies running drug trials to now being dominated by smaller companies without a product in the market yet. Regarding emerging trends, Zolman anticipates artificial intelligence will have a transformational impact on the industry. He also highlights the importance of knowing when to say "no" and making definitive decisions based on customer's needs, aligning company focus to customer growth, and maintaining transparency in their operations. 5 Key Points: Toban Zolman is the CEO of Kivo, with over 20 years of leadership experience in developing, deploying, and validating computerized systems for clinical trials. Zolman's career began in the early 2000s at an electronic submission company, pioneering the transition from paper to electronic submissions for pharmaceutical companies globally, impacting 47 out of the top 50 Pharma companies in 16 countries. At Kivo, Zolman leverages his extensive background to innovate in life sciences by integrating technology and regulatory best practices to support emerging companies in developing and marketing new drugs efficiently. Kivo stands out in the life sciences space by blending deep clinical and regulatory experience with enterprise SaaS expertise, offering a unique approach to accelerating drug development and approval processes. Zolman emphasizes the importance of adaptability, saying no to maintain focus, and the potential transformative impact of AI on drug development, viewing it as both an intimidating and exciting challenge for the future.
/episode/index/show/lssuccess/id/30302638
info_outline
Revolutionizing Patient & Physician Exp. through Digital First Strategies
03/03/2024
Revolutionizing Patient & Physician Exp. through Digital First Strategies
Revolutionizing Patient and Physician Experiences through Digital First Strategies - In this week's episode of Life Science Success, we dive into the intersection of digital innovation and healthcare commercialization with leaders from Indegene, a company revolutionizing patient and physician experiences through digital-first strategies. We'll explore the journeys of Nancy Phelan, a biopharma commercial strategy expert; Jeff Rothstein, a marketing visionary who has significantly expanded Indegene's brand and capabilities; and Kevin Patterson, a strategic thinker in medical solutions, as they share insights on driving healthcare forward in today's complex landscape. Key Takeaways: Interdisciplinary Innovation: The convergence of diverse backgrounds and expertise is driving innovation in healthcare, emphasizing the importance of storytelling and engagement in healthcare marketing. Digital Transformation: The shift towards digital and data-driven strategies is revolutionizing patient and physician experiences, making healthcare more personalized and accessible. AI's Growing Influence: Artificial intelligence is poised to transform healthcare delivery and treatment, with current applications representing just the tip of the iceberg. Navigating Market Access Challenges: Successfully bringing new treatments to market requires overcoming regulatory and accessibility hurdles, highlighting the need for strategic market access planning. Optimism for the Future: Despite challenges, there's a strong sense of optimism about the future of healthcare, driven by technological advancements and a commitment to improving patient care.
/episode/index/show/lssuccess/id/30207373
info_outline
Donald Zinn - Vice President US Business - BD&L - Crossject
02/17/2024
Donald Zinn - Vice President US Business - BD&L - Crossject
This week on Life Science Success, we're excited to welcome Donald Zinn, a seasoned professional with nearly three decades of experience in the biotech, pharmaceutical, and medical device industries. Beyond his executive roles, Don contributes to the National Institutes of Health (NIH) as a Commercialization Grant Reviewer and has played a pivotal role at Crossject, leading their needle-free auto-injector platform to global success since the onset of COVID. Donald Zinn's Background and Experience: Donald Zinn, the Vice President of US Business at Crossject, has nearly 30 years of experience in the life sciences industry. He started his career with an undergraduate degree from UMBC and went on to innovate in the field by inventing dry process microarray during his time at the Uniform Services University. His journey included roles such as lab manager at Georgetown University's HIV Center, and leadership positions in companies focused on oncology, infectious diseases, and more. Crossject's Needle-Free Auto Injector: Zinn is part of the Crossject team, working on a needle-free auto injector, which he finds to be an exciting and innovative technology. This device is designed to deliver medications quickly and without the need for needles, addressing needle phobia and improving patient compliance. Demonstration of the Injector's Ease of Use: During the podcast, a demonstration was discussed showing how the injector works, including its ability to administer medication through clothing. This feature is particularly advantageous in emergency situations where speed and ease of use are critical. Focus on Partnerships and Market Expansion: Zinn emphasizes the importance of finding the right partners worldwide to distribute Crossject's needle-free injector. The company aims to select partners based on their expertise and market presence to ensure the technology is accessible to a broad audience. Future Prospects and Industry Impact: The conversation highlighted the potential of Crossject's technology to revolutionize drug delivery, especially for emergency medications like epinephrine. The ease of use, coupled with the effectiveness of the needle-free injector, presents a significant advancement in patient care and medication administration.
/episode/index/show/lssuccess/id/29999048
info_outline
Dr. Kate Broderick - Chief Innovation Officer Maravai
02/03/2024
Dr. Kate Broderick - Chief Innovation Officer Maravai
In this episode of Life Science Success, my guest is Dr. Kate Broderick. Dr. Broderick has more than 15 years of experience in the life science industry. A recognized vaccine expert, Dr. Broderick has a broad background in device and product development in the DNA therapeutic and drug delivery fields. She also actively works with teams at TriLink BioTechnologies, a Maravai company, to advance its global reagents and manufacturing services. Dr. Kate Broderick's Background: Originally from Scotland, Kate Broderick's academic journey began with using animals as models for human diseases. Her passion lies at the intersection of science and clinical application, leading her to focus on DNA therapeutics and drug delivery fields in the United States, particularly after her postdoctoral work at UCSD. Focus on DNA and RNA Technologies: Dr. Broderick is motivated by the fundamental roles of DNA and RNA in medicine. She discusses the potential of these molecules to revolutionize treatments, vaccines, and therapies, foreseeing a future where new medical solutions are developed using these technologies. Career Development and Innovation: Throughout her career, Dr. Broderick has embraced various roles beyond her scientific training, including clinical development and finance, which have enriched her understanding of product development and corporate strategy within biotech startups. Role as Chief Innovation Officer at Maravai: In her current role, Dr. Broderick emphasizes the importance of innovation in staying ahead in the fast-paced field of life sciences. She discusses fostering collaborative environments for scientists, integrating client needs into R&D, and focusing on structured innovation to drive the company's mission forward. Concerns and Future Outlook: Dr. Broderick expresses concerns about vaccine hesitancy and misinformation, emphasizing the need for better communication in the scientific community. She is excited about the future of nucleic acid medicines, predicting significant advancements in treating various diseases and developing new vaccines within the next decade.
/episode/index/show/lssuccess/id/29783588
info_outline
Thomas Rademacher MD, PHD - CEO Emergex
02/03/2024
Thomas Rademacher MD, PHD - CEO Emergex
In this episode of Life Science Success, my guest is Dr. Thomas Rademacher. Professor Rademacher, MD, PhD, co-founded Emergex and has served as CEO since the Company’s formation. He is an Emeritus Professor of Molecular Medicine at University College London (UCL) and a serial entrepreneur. Dr. Thomas Rademacher, MD, PhD, is the co-founder and CEO of Emergex, with a background as an Emeritus Professor of Molecular Medicine at the University College of London and a serial entrepreneur. His career has oscillated between academic and entrepreneurial roles, adhering to the philosophy of not staying in the same job for more than ten years. Rademacher's academic foundation in hardcore biochemistry was established during his PhD at the University of Wisconsin Madison. This rigorous training in biochemistry has been a cornerstone throughout his career, enabling him to navigate and innovate in the complex field of molecular medicine. His work has significantly contributed to the field of monoclonal antibodies, starting with foundational research at Oxford and involving the use of Chinese hamster ovary (CHO) cells. This work was pivotal for the development of recombinant proteins and monoclonal antibodies, leading to advancements in medicine. Rademacher has been involved in groundbreaking research and entrepreneurial ventures, including the Glycobiology Institute, which attracted interest from major corporations like Monsanto. His work has led to significant scientific advancements and the formation of companies that have had substantial impacts on the medical and biotechnological landscapes. He is currently focused on challenges in vaccinology and immunology, particularly in developing vaccines that activate the cellular immune response to fight viral infections effectively. Rademacher's innovative approach involves utilizing quantum-confined gold clusters and micro-needle technology to enhance vaccine delivery and efficacy.
/episode/index/show/lssuccess/id/29783498
info_outline
Ronan O’Hagan - President & CEO, Bectas Therapeutics Inc.
01/27/2024
Ronan O’Hagan - President & CEO, Bectas Therapeutics Inc.
Ronan O’Hagan, President & CEO, Bectas Therapeutics Inc. Rónán is a founder and the President and Chief Executive Officer for Bectas Therapeutics Inc. He has over 20 years of experience in oncology R&D including bringing over 20 molecules through IND and into clinical development and helping to guide 4 drugs through clinical development to FDA approval. Ronan O'Hagan is the President and CEO of Bectas Therapeutics, a cancer drug discovery and development company with over 20 years of experience in oncology R&D. He has been instrumental in advancing over 20 molecules through IND (Investigational New Drug) to clinical development and guiding four drugs through clinical trials to FDA approval. His approach at Bectas Therapeutics focuses on utilizing insights from human patients' immune responses to develop precision therapies, aiming to find the right drug for the right patient. This approach stems from his belief that understanding cancer's complexity requires a deep understanding of patients themselves. O'Hagan's career includes significant roles in various organizations: Chief Scientific Officer at Apricity Health and Exilio Therapeutics, leader of the Oncology Discovery team at Merck Research Labs, and involvement in a biotech startup originating from Dana Farber Cancer Institute. He emphasizes the importance of values like focusing on patients, people, and proof of concept in drug development. He believes in balancing innovation with discipline and highlights the need for collaborative but strong leadership in the pharmaceutical industry. O'Hagan discusses the challenges and triumphs of drug development, stressing the importance of speed in bringing therapies to patients and the need for alignment around core values within a team. He also underlines the role of precision in enhancing the effectiveness of immune therapies and the necessity of inclusive research to benefit diverse patient populations.
/episode/index/show/lssuccess/id/29675573
info_outline
Matthew Hill, Ph.D. - Founder and CEO of Elegen Corp
01/27/2024
Matthew Hill, Ph.D. - Founder and CEO of Elegen Corp
In this episode of Life Science Success, my guest is Matt Hill, Ph.D. Matt is founder and CEO of Elegen Corp., a privately-held company based in the San Francisco Bay Area committed to revolutionizing synthetic biology workflows with innovative DNA writing technology. Background and Experience: Matt Hill has a Ph.D. in genetics from Stanford University and was initially attracted to the Bay Area for its vibrant startup ecosystem. After completing his Ph.D., he joined Nera, a leading molecular diagnostics company, where he contributed to product development and new capabilities, particularly in massively multiplex PCR technology. Journey to Founding Elegen: Hill's experience at Nera, especially in DNA synthesis and production challenges, led him to identify DNA production as a critical bottleneck in life sciences. His interest in solving complex problems and connecting technology areas motivated him to found Elegen to address these challenges in DNA synthesis and production. Elegen's Impact and Infinia DNA: Elegen's product, Infinia DNA, aims to streamline workflows in life sciences, providing researchers with faster, more accurate DNA synthesis. This technology impacts various fields, including therapeutics and synthetic biology, by enabling quicker and more efficient product development cycles. Leadership and Vision: As a leader, Hill emphasizes inspiration, encouragement, and problem-solving. He discusses the importance of Elegen's technology in advancing fields like personalized therapeutics and its potential in addressing major health challenges. Hill also highlights the need for more investment in foundational research and development to foster scientific progress.
/episode/index/show/lssuccess/id/29675508
info_outline
Ross Jackson - The guy who wrote two books about patient recruitment
01/21/2024
Ross Jackson - The guy who wrote two books about patient recruitment
In this episode of Life Science Success, Ross Jackson, the guy who wrote two books about patient recruitment, is returning to tell us about his new patient recruitment book. Ross is a specialist in patient recruitment for clinical trials, having helped deliver many thousands of patient registrations for clients in the UK, Europe, and the US. The key highlights from the interview: Ross Jackson is a specialist in patient recruitment for clinical trials with experience in the UK, Europe, and the US. He has authored two books on the subject. His career journey began in digital marketing, where he initially recruited patients for a doctor's new treatment. Over time, he shifted his focus to healthcare and clinical trial recruitment. Patient recruitment faces challenges related to awareness and access. Many people are unaware of clinical trials, and misconceptions like being seen as "guinea pigs" persist. Lack of understanding about the importance of clinical research compounds the issue. Ross Jackson's first book focused on using Facebook ads for patient recruitment. It aimed to make it easier for research sites and others to access potential trial participants effectively. His new book takes a unique approach, featuring a fictional character named Josh Black, a puzzle solver who tackles patient recruitment challenges. The book explores various aspects of patient recruitment and aims to make the topic more accessible and engaging. Ross emphasizes the need for collaboration within the industry and the potential impact of AI, particularly natural language processing, in improving patient recruitment processes. He also mentions his excitement about attending a conference and watching his first Super Bowl in Orlando, highlighting his interest in sports and the upcoming event. The interview concludes with gratitude for sharing information about his new book and the hope that it will benefit those interested in patient recruitment. The book is available on Amazon.
/episode/index/show/lssuccess/id/29582658
info_outline
Dr. Lishan Aklog - CEO of Lucid Diagnostics
01/15/2024
Dr. Lishan Aklog - CEO of Lucid Diagnostics
In this episode of Life Science Success, my guest is Dr. Lishan Aklog. Dr. Aklog is the CEO of Lucid Diagnostics he also co-founded and has served as Chairman and Chief Executive Officer of Lucid’s parent company, PAVmed Inc (Nasdaq: PAVM) since its inception in 2014, and as Executive Chairman of PAVmed’s other major subsidiary, digital health company Veris Health Inc., since its inception. Dr. Lishan Aklog's Background: Dr. Aklog, CEO of Lucid Diagnostics and executive chairman of PAVmed’s subsidiary Varys Health, was a cardiothoracic surgeon with a strong interest in technological innovation in medicine. He has an extensive background in academic cardiac surgery and was actively involved in medical device innovation. Transition to Entrepreneurship: Transitioning from a successful career in cardiac surgery, Dr. Aklog co-founded Lucid Diagnostics and PAVmed. He ventured into medical device entrepreneurship, focusing on developing and commercializing innovative technologies. He was instrumental in creating and selling medical devices, notably a device for non-surgically removing clots. Lucid Diagnostics and Focus on Cancer Detection: Under Dr. Aklog’s leadership, Lucid Diagnostics specializes in early cancer detection, particularly esophageal cancer. Dr. Aklog emphasizes the importance of pre-cancer detection and prevention, highlighting the challenges in raising awareness and adherence to screening guidelines. Challenges and Achievements: A significant challenge in Dr. Aklog's journey has been raising capital to bring innovative technologies to market. Despite these challenges, Lucid Diagnostics has made substantial progress, especially in gaining payer coverage and launching large-scale screening programs. Leadership and Vision: Dr. Aklog's leadership philosophy centers on building a culture of success, teamwork, and innovation. He stresses the importance of surrounding oneself with talented individuals and working cohesively towards a shared mission, with a particular focus on impacting patient lives through advanced medical technologies.
/episode/index/show/lssuccess/id/29496038
info_outline
Roee Hevrony - CFO of ImmunoBrain Checkpoint
01/14/2024
Roee Hevrony - CFO of ImmunoBrain Checkpoint
In this episode of Life Science Success my guest is Roee Hevrony. Roee is the CFO of ImmunoBrain Checkpoint. Prior to joining IBC in 2015, Roee worked for Babcock Power, Inc. in its nuclear power generation unit as a business controller and started his career as an investment banker with Merrill Lynch. The podcast features an interview with Roee Hevrony, the CFO of ImmunoBrain Checkpoint. Roee Hevrony discusses his background, which includes growing up in Israel and working in investment banking before joining ImmunoBrain. ImmunoBrain is focused on a novel approach to treating neurodegenerative diseases by targeting the immune system rather than the brain itself. The company has been conducting research for nine years, expanding from basic research to clinical studies, with a unique therapy approach. Roee Hevrony emphasizes the importance of long-term vision and patience in the pharmaceutical industry, especially in the field of neurodegeneration.
/episode/index/show/lssuccess/id/29474598
info_outline
Tom Hartman - President & CEO - International Society of Pharmaceutical Engineering (ISPE)
01/10/2024
Tom Hartman - President & CEO - International Society of Pharmaceutical Engineering (ISPE)
In this episode of Life Science Success, my guest is Tom Hartman. Tom is the President and CEO of the International Society of Pharmaceutical Engineering (), Tom leads a global network of 20,000+ professionals spanning the complete pharmaceutical lifecycle. In this edition of Life Science Success, Don Davis interviews Tom Hartman, the president and CEO of the International Society of Pharmaceutical Engineering (ISPE). They discuss Hartman's career journey and the role of the ISPE in the life sciences industry. Hartman discusses the critical role of the society's volunteer network and emphasizes the importance of speed, quality, and solid decision-making in the industry. Concerns about industry shortages, workforce challenges, and readiness for future potential pandemics also arise. Hartman highlights several exciting incursions, such as the 'Facility of the Year Award' and ISPE's workforce of the future initiative. The interview sheds light on the ISPE's strategic goals and the overall current industry landscape and trends.
/episode/index/show/lssuccess/id/29434608
info_outline
James Foster CEO & Nigel McCracken COO - Virax Biolabs
01/06/2024
James Foster CEO & Nigel McCracken COO - Virax Biolabs
In this episode of the Life Science Success Podcast my guests are James Foster, CEO of Virax Labs and Nigel McCracken COO of Virax Labs. Virax Labs is a global biotechnology company specializing in the development of innovative diagnostic solutions. They focus on T-cell testing and immune profiling, with a novel portfolio of FluoroSpot T-cell diagnostics aimed at indications associated with chronic inflammation and T-cell exhaustion. Podcast Overview: The first "Life Science Success" podcast episode in 2024 features James Foster, CEO, and Nigel McCracken, COO, of Virax Biolabs. James Foster's Background: James Foster, CEO of Virax Biolabs, co-founded the company about 10 years ago. Initially starting in finance, he shifted to biotech and diagnostics due to his entrepreneurial interests, particularly influenced by the 2008 financial crisis. His goal is to develop comprehensive immune profiling in-vitro diagnostics (IVDs), focusing on early diagnosis of post-viral syndromes, chronic inflammation, and T-cell exhaustion. Virax Biolabs' Mission and Technology: Virax is dedicated to creating innovative diagnostic solutions, particularly their T-cell testing platform. This platform aims to address significant health issues like long COVID, affecting millions in the US and Europe. Foster emphasizes the importance of early detection in disease progression and the role of the immune system in combating pathogens. Nigel McCracken's Role and Insights: As COO, Nigel McCracken plays a crucial role in scaling Virax from a small team to a larger organization. He discusses the importance of strategic focus, effective decision-making, and the development of companion diagnostics, which are essential for personalized medicine, especially in oncology. Future Outlook and Challenges: Both Foster and McCracken highlight the challenges in biotech, including the need for innovation, execution, and efficient leadership. They foresee an increasing burden on healthcare systems due to post-viral syndromes and chronic conditions. The podcast also touches on the potential of venture capital in fostering new ideas and innovations in the biotech sector.
/episode/index/show/lssuccess/id/29369538
info_outline
AJ Mellott-CEO and Co-Founder Ronawk
12/17/2023
AJ Mellott-CEO and Co-Founder Ronawk
In this episode of Life Science Success, we are welcoming back Dr. AJ Mellott. Dr. Mellott is the CEO and Co-Founder, Ronawk manufacturer of customized tissue-mimetic technology that is advancing science. Dr. AJ Mellott is the CEO and co-founder of Ronawk, a company that specializes in creating hydrogel substrates that mimic various tissues in the human or animal body. Ronawk's tissue mimetic technology is used in cell culture to produce high-quality, active cells that are valuable for medical and diagnostic applications. The company has recently expanded and moved to Overland Park, Kansas, and has experienced significant growth in its team and production practices. Ronawk's technology has facilitated collaborations between researchers in different fields and has lowered barriers to experimentation and innovation in the life sciences. Dr. Mellott is excited about the potential of AI and machine learning to streamline research processes and the personalized screening of therapies for patients, ultimately improving healthcare outcomes.
/episode/index/show/lssuccess/id/29114838
info_outline
Dr. Paul Song-CEO and Vice Chairman of NKGen
12/17/2023
Dr. Paul Song-CEO and Vice Chairman of NKGen
In this episode of Life Science Success, my guest is Dr Paul Song. Dr. Song has served as Chief Executive Officer and Vice Chairman of NKGen since December 2022. Dr. Paul Song, CEO and Vice Chairman of NKGen since December 2022, shares his background as a radiation oncologist and his journey into biotech. Dr. Song talks about the importance of natural killer cells in the body's defense against diseases and their potential in treating conditions like Alzheimer's. NKGen's phase one trial showed promising results, with 90% of patients either stabilizing or improving in Alzheimer's treatment. NKGen is also exploring the use of natural killer cells in combination with other cancer therapies to enhance their effectiveness while minimizing side effects.
/episode/index/show/lssuccess/id/29114738
info_outline
David Sanders and Tony Paquin-Securing America's Pharmaceutical Supply
12/09/2023
David Sanders and Tony Paquin-Securing America's Pharmaceutical Supply
In this episode of Life Science Success, we are talking about Securing America's Pharmaceutical Supply with David Sanders and Tony Paquin. We are going to discuss derisking the supply chain and building resilience. Don, is joined by guests, David Sanders and Tony Paquin. They discuss the importance and challenges of securing America's medical supply chain. David introduces himself as the Vice President of Government Affairs at Coherence Biosciences and Executive Director at Securing America's Medicine and Supply, and Tony as the CEO and co-founder of iRemedy Healthcare, an AI-driven supply chain platform. They delve into the impacts of the COVID-19 pandemic on these supply chains, their effort in repatriating pharmaceutical supply and manufacturing back in America, and the role of innovation in overcoming the costs and barriers involved. Tony also mentioned his book, "The End of Us," which talks about this same issue.
/episode/index/show/lssuccess/id/29000848
info_outline
Andrea Henderson - Partner in the Life Sciences, Healthcare, Diversity, CEO & Board - DHR Global
12/09/2023
Andrea Henderson - Partner in the Life Sciences, Healthcare, Diversity, CEO & Board - DHR Global
My guest today on the Life Science Success Podcast is Andrea Henderson. Andrea is a Partner in the Life Sciences, Healthcare, Diversity, CEO & Board practices at DHR Global where she is an executive talent solutions strategist. Andrea Henderson, an Executive Talent Solutions Strategist, and they delve into Andrea's career journey, which started with a passion for diplomacy and evolved into a focus on talent management and diversity in the corporate world. Key Takeaways: Operational Excellence: Don emphasizes the significance of operational excellence in the life sciences industry, particularly the importance of value stream mapping. Career Evolution: Andrea's career journey highlights the unpredictable nature of career paths. Her transition from diplomacy to talent management and executive search underscores the importance of adaptability and problem-solving skills. Diversity and Inclusion: Andrea discusses the role of diversity and inclusion in executive-level roles, emphasizing the need to consider a wide range of perspectives to build the best teams. Impactful Leadership: Don and Andrea touch on leadership styles, with Andrea describing her leadership style as collaborative, visionary, and empowering. They also discuss the importance of authenticity, trust-building, and clear communication in leadership. Championing Change: Andrea expresses her excitement about the various avenues available to impact the future, particularly in promoting diversity and creating a more inclusive corporate environment.
/episode/index/show/lssuccess/id/29000718
info_outline
Sucheshna Patil - CEO and founder of MobilityZ Health
12/03/2023
Sucheshna Patil - CEO and founder of MobilityZ Health
In this episode of Life Science Success, my guest is Sucheshna Patil. She is the CEO and founder of MobilityZ Health. A health-focused biotech engineer, innovator, and researcher building health technology products. Mobility Z Health's Focus: The company specializes in orthopedic care, particularly addressing the problem of delays in orthopedic appointments. Their goal is to provide early care and diagnosis for musculoskeletal injuries, reducing backlogs in orthopedic care. Transition from Humans in Space: Although the company initially operated as "Humans in Space," it later transitioned to the name "Mobility Z Health" to better align with its focus on healthcare and orthopedic solutions. Multifaceted Background: Sucheshna Patil has a background as a biotech engineer and researcher, with a passion for healthcare innovation. She drew from her experiences in healthcare, research, and engineering to develop solutions for musculoskeletal injuries. User-Friendly Approach: Mobility Z Health places a strong emphasis on user experience and user-friendliness in its products to ensure that a wide range of people, including patients and older generations, can use them. Development Stage: The company is currently in the alpha testing phase, with private access for patients and doctors who want to use the product. A beta version for broader consumer use is expected to launch in January.
/episode/index/show/lssuccess/id/28900348
info_outline
Mara Holinger PhD, RAC - SVP and co-founder of Quantum Regulatory Solutions
12/03/2023
Mara Holinger PhD, RAC - SVP and co-founder of Quantum Regulatory Solutions
In this episode of Life Science Success, my guest is Mara Holinger. Mara is the SVP and co-founder of Quantum Regulatory Solutions. She has extensive experience in assisting pharmaceutical and biotech firms with preparing their regulatory pathway, providing regulatory input for clinical trial designs and clinical development plans, performing gap analyses for preclinical testing and writing regulatory applications. Key points covered in this interview: Background and Expertise: Mara Holinger has a strong background in Regulatory Affairs, with a Ph.D. in a related field. She also highlighted her co-founders' scientific expertise, making their team unique in the regulatory consulting field. Client Base: Quantum Regulatory Solutions primarily serves small to midsize pharmaceutical companies, offering a range of services beyond just regulatory strategy, including pre-meeting support and long-term pathway planning. Team Collaboration: Mara emphasized the importance of collaboration within her team, combining their diverse skill sets to provide comprehensive solutions to clients. This collaborative approach sets them apart from others in the field. Leadership and Empowerment: She mentioned the value of strong leadership and role models who encouraged her to speak up and not apologize for her opinions. This empowerment has been crucial in her career. Passion for Problem-Solving: What excites Mara is the opportunity to solve complex puzzles in the regulatory space, working closely with various stakeholders to ensure that innovative therapies can navigate the regulatory process successfully.
/episode/index/show/lssuccess/id/28900313